Bubs Lodges Letter of Intent with FDA

• U.S. Food and Drug Administration (FDA) releases clear regulatory pathway for permanent market access for Bubs® Infant Formula and seven other manufacturers that received enforcement discretion. • Bubs Australia today confirms lodgement of the Letter of Intent for continued enforcement discretion for all six Bubs® Infant Formula products and commits to fully complying with applicable regulatory